Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for AORT given its acquisition-driven medical device model where revenue growth, integration costs, and debt-financed dealmaking must be assessed together.

Composite Trajectory: Mixed

Annual results show clear improvement: revenue grew 14% to $441.3M (10-K 2025-12-31, Consolidated Statements of Operations), net income turned positive at $9.8M from a -$13.4M loss (10-K 2025-12-31, Consolidated Statements of Operations), and total debt fell 32% to $215.1M after convertible note settlement (10-K 2025-12-31, Note 10). However, near-term quarterly trends reflect acquisition integration: H1 2026 G&A surged to 58% of revenue from 53% in H1 2025 driven by $12.5M Endospan transaction costs (10-Q 2026-06-30, MD&A), total principal debt jumped to $370M from $220M after the $150M New Delayed Draw Term Loan draw (10-Q 2026-06-30, Liquidity), and contingent consideration liabilities rose to $96.5M from $60.6M (10-Q 2026-06-30, Balance Sheet). Core product revenue growth remains strong (+14% constant currency H1 2026), but earnings and leverage are temporarily pressured by deal execution.

2. Red Flags

• Operating income declined 13% YoY in FY2025 ($33.7M vs $38.9M) despite 14% revenue growth, driven by a $7.7M Ascyrus contingent consideration fair value loss (vs $11.0M gain in 2024) and $3.5M net cybersecurity costs (10-K 2025-12-31, MD&A)
• G&A as percentage of revenue jumped to 51% in FY2025 from 47% in FY2024, and further to 63% in Q2 2026 from 51% in Q2 2025, primarily from Endospan acquisition costs ($11.7M in Q2, $12.5M H1) (10-Q 2026-06-30, MD&A)
• Free cash flow collapsed to $0.9M in FY2025 from $11.0M in FY2024 as capex rose to $39.0M from $11.2M for Austin building purchases (10-K 2025-12-31, Cash Flows)
• Total principal indebtedness increased 68% to $370M at June 30, 2026 from $220M at December 31, 2025 following the $150M Endospan acquisition borrowing (10-Q 2026-06-30, Liquidity)
• Contingent consideration liabilities rose 59% to $96.5M at June 30, 2026 from $60.6M at December 31, 2025, combining Ascyrus PMA milestone ($25M current) and Endospan earnout (10-Q 2026-06-30, Balance Sheet; 10-K 2025-12-31, Note 3)
• H1 2026 operating cash flow remained slightly negative (-$0.1M) despite revenue growth, pressured by Endospan transaction bonuses ($10.2M) and inventory build (10-Q 2026-06-30, Cash Flows)
• Accumulated other comprehensive loss improved sharply to -$2.7M from -$24.9M, driven by $22.2M foreign currency translation gains, masking equity volatility (10-K 2025-12-31, Consolidated Statements of Operations)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP results show sustained top-line momentum and profitability inflection: revenue compounded at ~12% over FY2023-2025 ($354.0M → $388.5M → $441.3M), gross margin held at 64-65%, and net income swung from -$30.7M to -$13.4M to +$9.8M (10-K 2025-12-31, Consolidated Statements of Operations). However, operating income peaked in FY2024 ($38.9M) and fell in FY2025 ($33.7M) due to a $18.7M swing in Ascyrus contingent consideration (gain to loss) and one-time cyber/launch costs. Quarterly trends confirm revenue durability (H1 2026 +14% YoY to $242.1M, 10% constant currency) but reveal significant cost absorption: H1 2026 G&A rose 25% to $140.6M (58% of revenue) including $12.5M Endospan deal costs, and R&D rose 30% to $17.9M (10-Q 2026-06-30, MD&A). Surgical sealants constant currency revenue declined 1-2% in H1 2026, while aortic stent grafts (+11% cc) and On-X (+17% cc) drove growth (10-Q 2026-06-30, MD&A).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow improved steadily: $18.8M (FY2023) → $22.2M (FY2024) → $39.9M (FY2025), driven by higher profitability and working capital improvements (10-K 2025-12-31, Consolidated Statements of Cash Flows). However, investing outflows accelerated from -$0.5M to -$28.2M to -$42.0M as capex surged to $39.0M (Austin facilities) and Endospan loan funding continued ($8M in FY2025, $17M in FY2024). Free cash flow (operating minus capex) consequently fell to $0.9M in FY2025 from $11.0M in FY2024. In H1 2026, operating cash flow improved slightly to -$0.1M from -$1.9M in H1 2025, but investing cash flow ballooned to -$139.9M (including $116.7M Endospan acquisition, $18.8M capex) and financing provided $152.9M (primarily $148.9M net term loan proceeds) (10-Q 2026-06-30, Cash Flows). Cash balances rose to $77.3M at June 30, 2026 from $64.9M at December 31, 2025 (10-Q 2026-06-30, Balance Sheet).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

FY2025 showed structural strengthening: total debt dropped 32% to $215.1M after $100M convertible note settlement, equity rose 62% to $448.2M (conversion added 4.3M shares), and current liabilities fell 34% excluding the new $20.7M current Ascyrus contingent consideration (10-K 2025-12-31, Balance Sheet; Note 10). Goodwill grew modestly to $254.1M (+5%) from FX. By June 30, 2026, the Endospan acquisition reversed leverage trends: total assets jumped 21% to $1.07B, goodwill surged 38% to $349.9M, acquired technology rose 21% to $149.3M, and long-term debt increased 69% to $363.4M (10-Q 2026-06-30, Balance Sheet). Total liabilities rose 33% to $579.7M while equity grew only 10% to $492.2M. Contingent consideration liabilities (Ascyrus + Endospan) totaled $96.5M vs $60.6M at year-end. Cash increased to $77.3M with $30M revolver availability (10-Q 2026-06-30, Liquidity).

6. Data Gaps

• Standalone quarterly income statements for Q1 2026, Q3 2025, Q4 2025, and Q1 2025 (only H1 and Q2 comparisons provided in 10-Q 2026-06-30 MD&A)
• Quarterly cash flow statements for Q2 2026, Q1 2026, Q3 2025, Q4 2025, Q1 2025 (only H1 aggregates in 10-Q 2026-06-30)
• Quarterly balance sheets for March 31, 2026 and September 30, 2025 (only June 30, 2026 and December 31, 2025 provided in XBRL)
• Segment-level quarterly gross margins and operating income (only revenue by segment in 10-Q 2026-06-30)
• FY2026 full-year outlook beyond H1 (no annual 10-K for 2026 yet filed)
• Detailed breakdown of the $11.7M Endospan transaction bonuses vs other G&A components in Q2 2026